Medicare Fee Schedule Blanks On Next-Gen Sequencing
This article was originally published in The Gray Sheet
Executive Summary
Labs and test makers say they are confused about what if anything Medicare contractors are paying for various molecular diagnostics including next-generation sequencing following CMS' recent release of codes and pricing for 2015. Meanwhile, industry groups are anxious that the agency has yet to issue a proposed rule to implement broader statutory changes to diagnostic price-setting.
You may also be interested in...
'Moonshot' Opportunities: Dx Reimbursement, Radiation Therapy Among Medtech Focal Points
Personalized-medicine advocates say Vice President Biden's "Cancer Moonshot" initiative is a great opportunity, but it should be putting more focus on the importance of Medicare policies in driving cancer innovation. There is also a push in the medtech space to raise the profile of radiation therapy as a central tool for treating cancer.
New CMS Lab Test Panel Meets To Make Payment Policy Recommendations
The Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests held its inaugural meeting Aug. 26 to begin work on recommending crosswalks and gapfills for more than 25 molecular tests codes.
Medicare Dx Payment System Will Be Market-Based, More Transparent Under New Law
A new law makes vast changes to how clinical laboratory tests will be reimbursed by Medicare over the long term. Although the changes ultimately may lead to payment reductions, both test kits makers and laboratories applaud the new provisions. Reimbursement will better reflect the value that lab tests bring to the health care system, they say.